Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
The effect of a new prolactin-lowering drug, FCE 21336 [1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'allylergoline-8'-beta-car bonyl)-urea diphosphate] was evaluated on the hormone-dependent MXT mouse mammary carcinoma. The compound at doses of 0.02, 0.2 and 2 mg/kg s.c., 5 days a week for 6 weeks, was effective against early tumors (start of treatment: 1 day after tumor transplantation), and was more potent than bromocriptine. When FCE 21336 was tested on advanced tumors (start of treatment: 24 days after tumor transplantation), tumor weight after 3 weeks of treatment with the doses of 0.2 and 2 mg/kg had increased 6 and 5 times, respectively, compared to an increase of 10 times for control groups.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D011388:Prolactin / Q000032:analysis / Q000502:physiology*
D000970:Antineoplastic Agents; D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin; D000077465:Cabergoline